Skip to main content
SpringerLink
Log in

Recombinant Antibody Candidates for Treatment of Prostate Cancer

  • Chapter
Prostate Cancer

Part of the book series: Contemporary Cancer Research ((CCR))

  • 1048 Accesses

Abstract

Understanding of the molecular basis of prostate cancer has led to development of newer treatment modalities. Identification of specific target molecules has led to the development of immune based therapeutic strategies for prostate cancer, such as therapy with vaccines and monoclonal antibody treatment. Chimeric and humanized antibodies directed against prostate cancer targets, such as prostate-specific membrane antigen, epidermal growth factor, and vascular endothelial growth factor have been developed. This chapter provides an overview of existing monoclonal antibody technology, clinical application, and future direction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kohler, G. and Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495–497.

    Article  PubMed  CAS  Google Scholar 

  2. Deb, N., Goris, M., Trisler, K., et al. (1996). Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin. Cancer Res. 2(8), 1289–1297.

    PubMed  CAS  Google Scholar 

  3. Mulligan, T., Carrasquillo, J. A., Chung, Y., et al. (1995). Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin. Cancer Res. 1(12), 1447–1454.

    PubMed  CAS  Google Scholar 

  4. Abdel-Nabi, H., Spaulding, F. F., Derby, L., Lamonica, D., and Glenn, S. (1995). Treatment of refractory prostate cancer with 90Y KC4. J. Nuclear Med. 36[Suppl], 213.

    Google Scholar 

  5. O’Donnell, R. T., DeNardo, S. J., Shi, X. B., et al. (1998). L6 monoclonal antibody binds prostate cancer. Prostate 37(2), 91–97.

    Article  PubMed  CAS  Google Scholar 

  6. Davis, C. G., Gallo, M. L., and Corvalan, J. R. (1999). Transgenic mice as a source of fully human antibodies for the treatment of cancer. Cancer Metastasis Rev. 18(4), 421–425.

    Article  PubMed  CAS  Google Scholar 

  7. Holliger, P. and Bohlen, H. (1999). Engineering antibodies for the clinic. Cancer Metastasis Rev. 18(4), 411–419.

    Article  PubMed  CAS  Google Scholar 

  8. Bander, N. H., Nanus, D. M., Milowsky, M. I., Kostakoglu, L., Vallabahajosula, S., and Goldsmith, S. J. (2003). Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Sem. Oncol. 30(5), 667–676.

    Article  CAS  Google Scholar 

  9. Hamilton, A., King, S., Liu, H. (1998). A novel humanized antibody against prostate specific membrane antigen (PSMA) for in vivo targeting and therapy. Proc. Am. Assoc. Cancer Res. 39, 440 (abstr).

    Google Scholar 

  10. Kellermann, S. A. and Green, L. L. (2002). Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr. Opin. Biotechnol. 13(6), 593–597.

    Article  PubMed  CAS  Google Scholar 

  11. Belldegrun, A., Bander, N. H., Lerner, S. P., Wood, D. P., and Pantuck, A. J. (2001). Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. J. Urol. 166(4), 1316–1321.

    Article  PubMed  CAS  Google Scholar 

  12. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R. (1994). Making antibodies by phage display technology. Ann. Rev. Immunol. 12, 433–455.

    Article  CAS  Google Scholar 

  13. DeNardo, S. J., Mirick, G. R., Kroger, L. A., et al. (1994). The biologic window for chimeric L6 radioimmunotherapy. Cancer 73(3 Suppl.), 1023–1032.

    Article  PubMed  CAS  Google Scholar 

  14. O’Donnell, R. T. DeNardo, S. J. Shi, X. B., et al. (1998). L6 monoclonal antibody binds prostate cancer. Prostate 37(2), 91–97.

    Article  PubMed  CAS  Google Scholar 

  15. Israeli, R. S., Powell, C. T., Fair, W. R., and Heston, W. D. (1993). Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 53(2), 227–230.

    PubMed  CAS  Google Scholar 

  16. Pinto, J. T., Suffoletto, B. P., Berzin, T. M., et al. (1996). Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin. Cancer Res. 2(9), 1445–1451.

    PubMed  CAS  Google Scholar 

  17. Carter, R. E., Feldman, A. R., and Coyle, J. T. (1996). Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. USA 93(2), 749–753.

    Article  PubMed  CAS  Google Scholar 

  18. Luthi-Carter, R., Barczak, A. K., Speno, H., and Coyle, J. T. (1998). Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J. Pharmacol. Exp. Ther. 286(2), 1020–1025.

    PubMed  CAS  Google Scholar 

  19. O’Keefe, D. S., Su, S. L., Bacich, D. J., et al. (1998). Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim. Biophys. Acta. 1443(1-2), 113–127.

    PubMed  CAS  Google Scholar 

  20. Horoszewicz, J. S., Kawinski, E., and Murphy, G. P. (1987). Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 7(5B), 927–935.

    PubMed  CAS  Google Scholar 

  21. Sweat, S. D., Pacelli, A., Murphy, G. P., and Bostwick, D. G. (1998). Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52(4), 637–640.

    Article  PubMed  CAS  Google Scholar 

  22. Bostwick, D. G., Pacelli, A., Blute, M., Roche, P., and Murphy, G. P. (1998). Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82(11), 2256–2261.

    Article  PubMed  CAS  Google Scholar 

  23. Troyer, J. K., Beckett, M. L., and Wright, G. L., Jr. (1995). Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer 62(5), 552–558.

    Article  PubMed  CAS  Google Scholar 

  24. Liu, H., Moy, P., Kim, S., et al. (1997). Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57(17), 3629–3634.

    PubMed  CAS  Google Scholar 

  25. Smith-Jones, P. M., Vallabhajosula, S., Navarro, V., Bastidas, D., Goldsmith, S. J., and Bander, N. H. (2003). Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med. 44(4), 610–617.

    PubMed  CAS  Google Scholar 

  26. Grauer, L. S., Lawler, K. D., Marignac, J. L., Kumar, A., Goel, A. S., and Wolfert, R. L. (1998). Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM’ protein in the LNCaP prostatic carcinoma cell line. Cancer Res. 58(21), 4787–4789.

    PubMed  CAS  Google Scholar 

  27. Murphy, G. P., Greene, T. G., Tino, W. T., Boynton, A. L., and Holmes, E. H. (1998). Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J. Urol. 160(6 Pt 2), 2396–2401.

    Article  PubMed  CAS  Google Scholar 

  28. Smith-Jones, P. M., Vallabhajosula, S., Navarro, V., Bastidas, D., Goldsmith, S. J., and Bander, N. H. (2003). Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med. 44(4), 610–617.

    PubMed  CAS  Google Scholar 

  29. Vallabhajosula, S., Smith-Jones, P. M., Navarro, V., Goldsmith, S. J., and Bander, N. H. (2004). Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 58(2), 145–145.

    Article  PubMed  CAS  Google Scholar 

  30. Bander, N. H., Nanus, D., Goldsmith, S., et al. (2000). Phase I trial of humanized monoclonal antibody (mAb) to prostate specific membrane antigen/extracellular domain (PSMAext). Proc. Am. Soc. Clin. Oncol. 19, 477a (abstr 1872).

    Google Scholar 

  31. Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., Goldsmith, S. J., and Bander, N. H. (2004). Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 22(13), 2522–2531.

    Article  PubMed  CAS  Google Scholar 

  32. Bander, N. H., Milowsky, M. I., Nanus, D., Kostakoglu, L., Vallabhajosula, S., Goldsmith, S. (2005). Phase 1 trial of 177Lutetium-labeled J591, a monoclonal antibody to prostate specific membrane antigen, in patients with androgenindependent prostate cancer. J. Clin. Oncol. 23(21), 4591–4601.

    Article  PubMed  CAS  Google Scholar 

  33. Vallabhajosula, S., Goldsmith, S. J., Hamacher, K. A., et al. (2005). Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y-and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J. Nucl. Med. 46(5), 850–858.

    PubMed  CAS  Google Scholar 

  34. Gong, M. C., Latouche, J. B., Krause, A., Heston, W. D., Bander, N. H., and Sadelain, M. (1999). Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (New York) 1(2), 123–127.

    CAS  Google Scholar 

  35. O’Donnell, R. T., DeNardo, S. J., DeNardo, G. L., et al. (2000). Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice. Prostate 44(3), 187–192.

    Article  PubMed  CAS  Google Scholar 

  36. Ross, J. S., Schenkein, D. P., Pietrusko, R., et al. (2004). Targeted therapies for cancer 2004. Am. J. Clin. Pathol. 122(4), 598–609.

    Article  PubMed  CAS  Google Scholar 

  37. Ziada, A., Barqawi, A., Glode, L. M., et al. (2004). The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60(4), 332–337.

    Article  PubMed  CAS  Google Scholar 

  38. Small, E. J., Bok, R., Reese, D. M., Sudilovsky, D., and Frohlich, M. (2001). Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Sem. Oncol. 28(4 Suppl. 15), 71–76.

    Article  CAS  Google Scholar 

  39. McCarthy, M. (2003). Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 361(9373), 1959.

    Article  PubMed  Google Scholar 

  40. Sparano, J. A., Gray, R., Giantonio, B., O’Dwyer, P., and Comis, R. L. (2004). Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin. Cancer Res. 10(4), 1206–1211.

    Article  PubMed  CAS  Google Scholar 

  41. Phan, G. Q., Yang, J. C., Sherry, R. M., et al. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100(14), 8372–8377.

    Article  PubMed  CAS  Google Scholar 

  42. Hurwitz, A. A., Foster, B. A., Kwon, E. D., et al. (2000). Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60(9), 2444–2448.

    PubMed  CAS  Google Scholar 

  43. Rajasekaran, S. A., Anilkumar, G., Oshima, E., et al. (2003). A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol. Biol. Cell. 14(12), 4835–4845.

    Article  PubMed  CAS  Google Scholar 

  44. DeNardo, S. J., DeNardo, G. L., Yuan, A., et al. (2003). Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin. Cancer Res. 9(10 Pt 2), 3938S–3944S.

    PubMed  CAS  Google Scholar 

  45. O’Donnell, R. T., DeNardo, S. J., Miers, L. A., et al. (2002). Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate 50(1), 27–37.

    Article  PubMed  CAS  Google Scholar 

  46. Meredith, R. F., Bueschen, A. J., Khazaeli, M. B., et al. (1994). Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J. Nucl. Med. 35(6), 1017–1022.

    PubMed  CAS  Google Scholar 

  47. Meredith, R. F., Khazaeli, M. B., Macey, D. J., et al. (1999). Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin. Cancer Res. 5(10 Suppl.), 3254s–3258s.

    PubMed  CAS  Google Scholar 

  48. Slovin, S. F., Scher, H. I., Divgi, C. R., et al. (1998). Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin. Cancer Res. 4(3), 643–651.

    PubMed  CAS  Google Scholar 

  49. Petrylak, D. P., Tangen, C. M., Hussain, M. H., et al. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.[see comment]. New Engl. J. Med. 351(15), 1513–1520.

    Article  PubMed  CAS  Google Scholar 

  50. Shah, R. B., Mehra, R., Chinnaiyan, A. M. et al. (2004). Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 64(24), 9209–9216.

    Article  PubMed  CAS  Google Scholar 

  51. Davis, M. I., Bennett, M. J., Thomas, L. M., and Bjorkman, P. J. (2005). Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl. Acad. Sci USA 102, 5981–5986.

    Article  PubMed  CAS  Google Scholar 

  52. Nanus, D. M., Milowsky, M. I., Kostakoglu, L., et al. (2003). Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J. Urol. 170(6 Pt 2), S84–88; discussion S88-S89.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Glickman Urological Institute, The Cleveland Clinic, Cleveland, OH

    Anoop M. Meraney MD & Warren W. D. Heston

  2. Department of Cancer Biology, Lerner Research Institute, Cleveland, OH

    Warren W. D. Heston

Authors
  1. Anoop M. Meraney MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Warren W. D. Heston
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Emory University School of Medicine, Atlanta, GA

    Leland W. K. Chung PhD

  2. Johns Hopkins University School of Medicine, Baltimore, MD

    William B. Isaacs PhD

  3. Prostate Cancer Foundation, Santa Monica, CA

    Jonathan W. Simons MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Meraney, A.M., Heston, W.W.D. (2007). Recombinant Antibody Candidates for Treatment of Prostate Cancer. In: Chung, L.W.K., Isaacs, W.B., Simons, J.W. (eds) Prostate Cancer. Contemporary Cancer Research. Humana Press. https://doi.org/10.1007/978-1-59745-224-3_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-224-3_21

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-696-2

  • Online ISBN: 978-1-59745-224-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation